Tvardi Therapeutics is trading 10.83% lower at $1.40 as broader markets weaken amid rising crude oil prices, inflation concerns and higher Treasury yields.
- The Nasdaq Composite is down 1.21%, and the S&P 500 is down 0.76%, creating a challenging backdrop for speculative biotech stocks.
- No company-specific announcement, earnings release, regulatory action or analyst downgrade was identified on September 23, 2026.
- A prior report said the company was removed from the S&P Global BMI Index; that event predates today’s decline.